Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Core Insights - Avalo Therapeutics, Inc. has appointed Kevin R. Lind to its Board of Directors, bringing over 20 years of experience in capital markets and biotechnology [1][2] - The company is advancing its lead asset, AVTX-009, through a Phase 2 clinical trial for hidradenitis suppurativa (HS), with topline data expected in mid-2026 [2][3] - Mr. Lind's previous experience includes leading Longboard Pharmaceuticals to a $2.6 billion acquisition, indicating his capability in driving value for shareholders [2] Company Overview - Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases [3] - The lead asset, AVTX-009, is a humanized monoclonal antibody targeting IL-1β, which plays a significant role in various inflammatory diseases [4] Product Details - AVTX-009 is designed to neutralize IL-1β activity, which is a pro-inflammatory cytokine involved in the pathogenesis of autoimmune disorders [4] - The drug is currently in a Phase 2 clinical trial for HS, a condition with significant unmet medical needs [3][4]